Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2024eJHaemOpen Access

Post‐stem cell transplant maintenance in FLT3mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib

View Full Paper
Ask AI
Bookmark
Share

Authors

KAKaram AshouriUniversity of Southern CaliforniaKCKrithika ChennapanUSC Norris Comprehensive Cancer CenterAMAnastasia MartynovaUniversity of Southern California

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ashouri et al. (2024) studied this question.

synapsesocial.com/papers/68e70efbb6db64358768899fhttps://doi.org/10.1002/jha2.885
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gilteritinib maintenance therapy after allogeneic hematopoietic stem cell transplantation in FLT3-mutated AML: A systematic review and meta-analysis2025
  2. 2Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapsed/refractory FLT3-mutated acute myeloid leukemia: A Japanese nationwide registry study2025
  3. 3Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations2026
  4. 4FLT3 inhibitors across the allogeneic transplant continuum in FLT3 -mutated acute myeloid leukemia: A systematic review and meta-analysis.2026
  5. 5Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib2026 · 2 citations